Monday, April 17, 2017 9:00 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “I’m extremely proud of the entire AmpliPhi team, including academic collaborators, clinical investigators and consultants, for their efforts in successfully positioning our phage technology to enter the Phase 2 development stage, which we expect will open additional […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-04-17 13:58:222018-01-04 14:02:42AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal
Friday, April 14, 2017 5:00 pm EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We believe the increased market price of our common stock expected to result following the implementation of the reverse stock split may improve the marketability and liquidity of our common stock and encourage interest and trading in […]
Purchase price of US$6.72 per share, or approximately US$85 million in aggregate Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually1 PARSIPPANY, N.J. & TULLAMORE, Ireland–(BUSINESS WIRE)–Apr. 13, 2017– Link here Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zoetis, through a wholly owned subsidiary (“Zoetis Bidco”), will purchase […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-04-13 14:06:122018-01-05 19:43:39Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals
Valencia, CA, Perth, Australia and London, United Kingdom, 7 April 2017 – link here The U.S. Food and Drug Administration has approved a further increase in the number of patients who can be treated in the United States with the ReCell® regenerative medical device under a compassionate use protocol, Avita Medical Ltd. (ASX: AVH), (OTCQX: […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-04-07 14:25:162018-01-04 14:28:01FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell®
CATEGORY: Featured Tuesday, April 4, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “AmpliPhi and our partners have produced promising clinical and nonclinical data demonstrating AmpliPhi’s phage cocktails are safe and active against a broad footprint of isolates, including those that are multidrug-resistant” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-04-04 14:20:482018-01-04 14:24:59AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences
Garth Sutherland, Adherium CEO & Founder, selected as a Speaker and author at the upcoming meeting, RDD Europe 2017 to be held April 25-28, 2017, at Palais des Congres d’Antibes, Nice (Antibes), France. Link here Garth will present on Thursday, April 27, during Session 3: Can Connected Devices Improve Respiratory Outcomes? 9.30 a.m. ‘Track and Remind’: Can […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-29 14:52:072018-01-04 14:53:21Come meet Adherium at RDD Europe 2017
A record number of people gathered across Auckland, Christchurch and Wellington to hear the finalists announced for the 2017 NZ Hi-Tech Awards. – link here Entries this year came from as far afield as Kaitaia and Invercargill which have resulted in a record number of entries being received, up 30% on last year. Wayne Norrie, […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-29 14:30:172018-01-04 14:31:45Adherium chosen as Finalist in NZ Hi-Tech Awards
Monday, March 27, 2017 4:11 pm EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “The growing incidence of antibiotic-resistant bacterial infections is a major health threat that is recognized by governments and health authorities around the world” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development […]
Valencia, CA, USA, Perth, Australia and London, United Kingdom, 23 March 2017 — Link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita’s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017. […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-23 14:41:082018-01-04 14:51:53Avita Medical to Present at Needham Healthcare Conference
Valencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 16 March 2017 — Link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office of A$974,908 for […]
/wp-content/uploads/2018/01/BSM_logo.png00keymaster/wp-content/uploads/2018/01/BSM_logo.pngkeymaster2017-03-16 14:53:542018-01-04 15:01:25Avita Announces $975k R & D Tax Incentive
AmpliPhi Biosciences Announces Positive Feedback from FDA on Phase 2 Development Proposal
/in Portfolio CompaniesMonday, April 17, 2017 9:00 am EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “I’m extremely proud of the entire AmpliPhi team, including academic collaborators, clinical investigators and consultants, for their efforts in successfully positioning our phage technology to enter the Phase 2 development stage, which we expect will open additional […]
AmpliPhi Biosciences Announces Planned One-for-Ten Reverse Stock Split
/in Portfolio CompaniesFriday, April 14, 2017 5:00 pm EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “We believe the increased market price of our common stock expected to result following the implementation of the reverse stock split may improve the marketability and liquidity of our common stock and encourage interest and trading in […]
Zoetis to Acquire Nexvet Biopharma, an Innovator in Monoclonal Antibody Therapies for Companion Animals
/in Pharmamark, Portfolio CompaniesPurchase price of US$6.72 per share, or approximately US$85 million in aggregate Acquisition to strengthen Zoetis’ pipeline in companion animal therapeutics for chronic pain, a global area estimated at US$400 million annually1 PARSIPPANY, N.J. & TULLAMORE, Ireland–(BUSINESS WIRE)–Apr. 13, 2017– Link here Zoetis Inc. (NYSE:ZTS) and Nexvet Biopharma plc (Nasdaq:NVET) today announced an agreement in which Zoetis, through a wholly owned subsidiary (“Zoetis Bidco”), will purchase […]
FDA Approves Increased Compassionate Use Patient Cases and Sites for ReCell®
/in Portfolio CompaniesValencia, CA, Perth, Australia and London, United Kingdom, 7 April 2017 – link here The U.S. Food and Drug Administration has approved a further increase in the number of patients who can be treated in the United States with the ReCell® regenerative medical device under a compassionate use protocol, Avita Medical Ltd. (ASX: AVH), (OTCQX: […]
AmpliPhi Biosciences Announces Presentations of Clinical and Preclinical Data from Studies with its Bacteriophage Technology at Two Scientific Conferences
/in Portfolio CompaniesCATEGORY: Featured Tuesday, April 4, 2017 6:50 am EDT – link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “AmpliPhi and our partners have produced promising clinical and nonclinical data demonstrating AmpliPhi’s phage cocktails are safe and active against a broad footprint of isolates, including those that are multidrug-resistant” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation […]
Come meet Adherium at RDD Europe 2017
/in Portfolio CompaniesGarth Sutherland, Adherium CEO & Founder, selected as a Speaker and author at the upcoming meeting, RDD Europe 2017 to be held April 25-28, 2017, at Palais des Congres d’Antibes, Nice (Antibes), France. Link here Garth will present on Thursday, April 27, during Session 3: Can Connected Devices Improve Respiratory Outcomes? 9.30 a.m. ‘Track and Remind’: Can […]
Adherium chosen as Finalist in NZ Hi-Tech Awards
/in Portfolio CompaniesA record number of people gathered across Auckland, Christchurch and Wellington to hear the finalists announced for the 2017 NZ Hi-Tech Awards. – link here Entries this year came from as far afield as Kaitaia and Invercargill which have resulted in a record number of entries being received, up 30% on last year. Wayne Norrie, […]
AmpliPhi Biosciences Reports 2016 Fourth-Quarter and Full-Year Results and Provides Corporate Highlights
/in Portfolio CompaniesMonday, March 27, 2017 4:11 pm EDT – Link here SAN DIEGO EmailPDFPrintRSS PUBLIC COMPANY INFORMATION: NYSEMKT: APHB “The growing incidence of antibiotic-resistant bacterial infections is a major health threat that is recognized by governments and health authorities around the world” SAN DIEGO–(BUSINESS WIRE)–AmpliPhi Biosciences Corporation (NYSE MKT: APHB), a global leader in the development […]
Avita Medical to Present at Needham Healthcare Conference
/in Portfolio CompaniesValencia, CA, USA, Perth, Australia and London, United Kingdom, 23 March 2017 — Link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that Adam Kelliher, Avita’s Chief Executive Officer will present at the 16th Annual Needham Healthcare Conference on 4 April 2017. […]
Avita Announces $975k R & D Tax Incentive
/in Portfolio CompaniesValencia, CA, USA, Perth, Australia and Cambridge, United Kingdom, 16 March 2017 — Link here Avita Medical Limited (ASX:AVH; OTCQX:AVMXY), a regenerative medicine company focused on the treatment of wounds and skin defects, today announced that it has received a Research and Development Tax Incentive cash rebate from the Australian Tax Office of A$974,908 for […]